Globus Medical(NYSE) GMED

Globus Medical creates tools and implants that help doctors fix back and bone problems. These products allow surgeons to repair spines, treat broken limbs, and manage chronic pain for their patients. The company makes it easier for hospitals and clinics to provide specialized care through advanced robotic technology.

What Globus Medical Makes

• Musculoskeletal Solutions: Includes spinal implants, bone grafts, and nerve-monitoring tools used in surgeries to treat injuries or degenerative diseases.
• Enabling Technologies: Advanced computer systems and robotic arms like the ExcelsiusGPS that help surgeons place implants with higher precision.
• Pain Management: Specialized electrical systems that send pulses to the spinal cord to block chronic pain signals for patients.
• Orthopedic Trauma: Plates, screws, and nails designed to help heal broken bones in the arms, legs, and hips.

Recent Strategic Moves

• Completed the acquisition of NuVasive in 2023 to expand its global reach and spinal product offerings.
• Acquired Nevro in the second quarter of 2025 to enter the spinal cord stimulation and chronic pain market.
• Purchased a share of a biotechnology company in 2024 to focus on developing solutions for stopping bleeding during surgery.
• Launched 9 new products in 2025, including the ExcelsiusXR wearable headset for guided navigation in the operating room.

A Competitive Engineering Focus

The company maintains a fast-paced development engine by keeping engineering and manufacturing facilities in-house. This integrated approach allows for rapid testing and constant updates based on direct feedback from surgeons across 65 countries.

The Financial Scorecard

• Revenue reached $826.4 million in Q4 2025, up 25.7% from the previous year.
• Net income climbed to $140.6 million in Q4 2025, representing a 430.6% increase year-over-year.
• Operating income rose to $171.7 million in Q4 2025, up 184.8% from $60.3 million in Q4 2024.
• Operating cash flow grew to $248.6 million in Q4 2025, an 18.2% increase over the prior year.
• International sales accounted for 19.4% of total sales during the fiscal year ended December 31, 2025.

Bottom Line

Globus Medical has transitioned from a specialized spine company into a broad musculoskeletal and technology provider. Its expansion into robotics and neuromodulation has diversified its business beyond traditional surgical implants.